Originally published as JCO Early Release 10.1200/JCO.2005.02.2194 on November 28 2005
Journal of Clinical Oncology, Vol 24, No 1 (January 1), 2006: pp. 25-35
© 2006 American Society of Clinical Oncology.
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
Sandrine Faivre,
Catherine Delbaldo,
Karina Vera,
Caroline Robert,
Stéphanie Lozahic,
Nathalie Lassau,
Carlo Bello,
Samuel Deprimo,
Nicoletta Brega,
Giorgio Massimini,
Jean-Pierre Armand,
Paul Scigalla,
Eric Raymond
From the Department of Medicine, Gustave-Roussy Institute, Villejuif, France; and SU11248 Working Group, Pfizer Co, Rome, Italy and New York, NY
Address reprint requests to Eric Raymond, MD, PhD, Head of the Department of Medical Oncology, Beaujon University Hospital, 100 Boulevard du Général Leclerc, Clichy, France; e-mail: eric.raymond{at}bjn.aphp.fr
PURPOSE: To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies.
PATIENTS AND METHODS: Sunitinib was given orally for 4 weeks every 6 weeks.
RESULTS: Twenty-eight patients received doses ranging from 15 to 59 mg/m2 (ranging from 50 mg every other day to 150 mg/d). Dose-limiting toxicities reported at the maximum-tolerated doses  75 mg/d were reversible grade 3 fatigue, grade 3 hypertension, and grade 2 bullous skin toxicity. Therefore, the recommended dose was 50 mg/d. At this dose, the main adverse effects were sore mouth, edema, and thrombocytopenia. Hair discoloration and yellow coloration of the skin were observed at doses 50 mg/d. Pharmacokinetic data indicate that potentially active target plasma concentrations 50 ng/mL can be achieved with moderate interpatient variability and a long half-life compatible with a single daily dosing. Six objective responses were observed in three renal cell carcinomas, one neuroendocrine tumor, one stromal tumor, and one unknown primary adenocarcinoma patient. At higher doses ( 75 mg/d), tumor responses were often associated with reduced intratumoral vascularization and central tumor necrosis, eventually resulting in organ perforation or fistula.
CONCLUSION: At the dose of 50 mg/d (4 weeks on, 2 weeks off), sunitinib displays manageable toxicity. Antitumor activity supports further studies in patients with renal cell carcinoma, gastrointestinal, neuroendocrine, and stromal tumors. Future studies may consider including prospective imaging techniques such as high frequency ultrasound to monitor tumor density.
S.F. and C.D. contributed equally to this work.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Related Editorial
- New Targets, Therapies, and Toxicities: Lessons to Be Learned
Walter M. Stadler
JCO 2006 24: 4-5
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
M. H. Chen, R. Kerkela, and T. Force
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Circulation,
July 1, 2008;
118(1):
84 - 95.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tarn, L. Rink, E. Merkel, D. Flieder, H. Pathak, D. Koumbi, J. R. Testa, B. Eisenberg, M. von Mehren, and A. K. Godwin
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
PNAS,
June 17, 2008;
105(24):
8387 - 8392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Lacouture, L. M. Reilly, P. Gerami, and J. Guitart
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
Ann. Onc.,
June 10, 2008;
(2008)
mdn389v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1110 - 1120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sarker, R. Molife, T.R. J. Evans, M. Hardie, C. Marriott, P. Butzberger-Zimmerli, R. Morrison, J. A. Fox, C. Heise, S. Louie, et al.
A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Clin. Cancer Res.,
April 1, 2008;
14(7):
2075 - 2081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Hiles and J. M. Kolesar
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
Am. J. Health Syst. Pharm.,
January 15, 2008;
65(2):
123 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Helgason, H. A. Mallo, H. Droogendijk, John.G. Haanen, A. A.M. van der Veldt, A. J. van den Eertwegh, and E. Boven
Brain Metastases in Patients With Renal Cell Cancer Receiving New Targeted Treatment
J. Clin. Oncol.,
January 1, 2008;
26(1):
152 - 154.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Oncologist,
December 1, 2007;
12(12):
1443 - 1455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. L. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
PNAS,
October 23, 2007;
104(43):
17069 - 17074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. de Bouard, P. Herlin, J. G. Christensen, E. Lemoisson, P. Gauduchon, E. Raymond, and J.-S. Guillamo
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
Neuro-oncol,
October 1, 2007;
9(4):
412 - 423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. M. van der Veldt, A. J. M. van den Eertwegh, K. Hoekman, F. Barkhof, and E. Boven
Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy
Ann. Onc.,
October 1, 2007;
18(10):
1747 - 1750.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mannavola, P. Coco, G. Vannucchi, R. Bertuelli, M. Carletto, P. G. Casali, P. Beck-Peccoz, and L. Fugazzola
A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake
J. Clin. Endocrinol. Metab.,
September 1, 2007;
92(9):
3531 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Saylor and T. R. Reid
Tumor Lysis Syndrome After Treatment of a Gastrointestinal Stromal Tumor With the Oral Tyrosine Kinase Inhibitor Sunitinib
J. Clin. Oncol.,
August 10, 2007;
25(23):
3544 - 3546.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Emmenegger, Y. Shaked, S. Man, G. Bocci, I. Spasojevic, G. Francia, A. Kouri, R. Coke, W. Cruz-Munoz, S. M. Ludeman, et al.
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice
Mol. Cancer Ther.,
August 1, 2007;
6(8):
2280 - 2289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Stein and K. T. Flaherty
CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma
Clin. Cancer Res.,
July 1, 2007;
13(13):
3765 - 3770.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Verweij and M. de Jonge
Multitarget Tyrosine Kinase Inhibition: [And the Winner Is...]
J. Clin. Oncol.,
June 10, 2007;
25(17):
2340 - 2342.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Rosen, R. Kurzrock, M. Mulay, A. Van Vugt, M. Purdom, C. Ng, J. Silverman, A. Koutsoukos, Y.-N. Sun, M. B. Bass, et al.
Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors
J. Clin. Oncol.,
June 10, 2007;
25(17):
2369 - 2376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H Kulke
Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
Endocr. Relat. Cancer,
June 1, 2007;
14(2):
207 - 219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Choi, C. Charnsangavej, S. C. Faria, H. A. Macapinlac, M. A. Burgess, S. R. Patel, L. L. Chen, D. A. Podoloff, and R. S. Benjamin
Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria
J. Clin. Oncol.,
May 1, 2007;
25(13):
1753 - 1759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Benjamin, H. Choi, H. A. Macapinlac, M. A. Burgess, S. R. Patel, L. L. Chen, D. A. Podoloff, and C. Charnsangavej
We Should Desist Using RECIST, at Least in GIST
J. Clin. Oncol.,
May 1, 2007;
25(13):
1760 - 1764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, et al.
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
Clin. Cancer Res.,
May 1, 2007;
13(9):
2643 - 2650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Thomas, T Trarbach, C Bartel, D Laurent, A Henry, M Poethig, J Wang, E Masson, W Steward, U Vanhoefer, et al.
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
Ann. Onc.,
April 1, 2007;
18(4):
782 - 788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Q.M. Chow and S. G. Eckhardt
Sunitinib: From Rational Design to Clinical Efficacy
J. Clin. Oncol.,
March 1, 2007;
25(7):
884 - 896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gridelli, P. Maione, F. Del Gaizo, G. Colantuoni, C. Guerriero, C. Ferrara, D. Nicolella, D. Comunale, A. De Vita, and A. Rossi
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
Oncologist,
February 1, 2007;
12(2):
191 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. George
Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma
Clin. Cancer Res.,
January 15, 2007;
13(2):
753s - 757s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-Y. Tsai, C.-H. Yang, T.-t. Kuo, H.-S. Hong, and J. W.C. Chang
Hand-Foot Syndrome and Seborrheic Dermatitis-Like Rash Induced by Sunitinib in a Patient With Advanced Renal Cell Carcinoma
J. Clin. Oncol.,
December 20, 2006;
24(36):
5786 - 5788.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, M. O. Karlsson, J. Brahmer, A. Spitz, M. Zhao, M. Hidalgo, and S. D. Baker
CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors
J Natl Cancer Inst,
December 6, 2006;
98(23):
1714 - 1723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Desai, L. Yassa, E. Marqusee, S. George, M. C. Frates, M. H. Chen, J. A. Morgan, S. S. Dychter, P. R. Larsen, G. D. Demetri, et al.
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
Ann Intern Med,
November 7, 2006;
145(9):
660 - 664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Kim, Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, et al.
An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases
J. Clin. Endocrinol. Metab.,
October 1, 2006;
91(10):
4070 - 4076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Faivre and E Raymond
Management of neuromuscular dose limiting toxicity at the early stage of drug development.
Ann. Onc.,
September 1, 2006;
17(9):
1343 - 1346.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
Oncologist,
July 1, 2006;
11(7):
753 - 764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Motzer, B. I. Rini, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, J. R. Merchan, G. Wilding, et al.
Sunitinib in patients with metastatic renal cell carcinoma.
JAMA,
June 7, 2006;
295(21):
2516 - 2524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Stadler
New Targets, Therapies, and Toxicities: Lessons to Be Learned
J. Clin. Oncol.,
January 1, 2006;
24(1):
4 - 5.
[Full Text]
[PDF]
|
|
|
|
